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Objective: Obesity, a risk factor for coronary artery disease (CAD), is associated with inflammation and
reactive oxygen species (ROS) production, while advanced glycation end-products, through their
receptor (AGER or RAGE), play an important role on these processes. The aim of this study was to analyze
the expression levels of RAGE, NADPH oxidase subunits, and catalase in adipose tissue in relation
with CAD.
Design and methods: Patients undergoing heart surgery were included in two groups: with and without
CAD. Epicardial adipose tissue (EAT) and subcutaneous adipose tissue (SAT) biopsies were analyzed for
gene expression by RT-quantitative PCR, immunohistochemistry, or western blot.
Results: RAGE mRNA and protein expression in SAT from patients with CAD was lower than in patients
without CAD. However, there was no change in EAT from patients with or without CAD. P22-PHOX and
RAGE gene expression were higher in EAT than in SAT, whereas catalase mRNA levels were lower.
NADPH oxidase subunits and catalase mRNA expression were not influenced by CAD. Whereas NADPH
oxidase-dependent oxidative response of SAT and EAT to lipid circulating levels could be different;
glycemic levels were not related with the analyzed genes expression.
Conclusions: This study demonstrates that RAGE expression in SAT, but not in EAT, is down-regulated in
patients with CAD with respect to those without CAD. Although changes were not observed for NADPH
oxidase subunits or catalase expression between CAD and non-CAD patients, a possible relationship
between ROS production and RAGE expression in adipose tissues cannot be ruled out.
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Obesity, associated with an increase in the size of
adipocytes and endocrine function of adipose tissue (1),
is related to cardiovascular disease and type 2 diabetes
(2). Thus, increased epicardial, pericardial, and subcu-
taneous fat is associated with the presence and severity
of coronary artery calcium (3). However, greater
attention has focused on visceral adipose tissue in
comparison with subcutaneous adipose tissue (SAT) in
the last few years because it is an important risk factor
for cardiovascular disease (4). In fact, in female
coronary artery disease (CAD) patients, a strong
decrease was observed in SAT of the legs in comparison
to healthy controls, with no significant shift in SAT to
the trunk (5), suggesting redistribution to visceral
adipose tissue. Epicardial adipose tissue (EAT) is thendocrinologyvisceral adipose tissue located in the atrioventricular
and interventricular grooves, adjacent to adventitia of
coronary arteries without fascia structures. This tissue
is a source of pro-inflammatory cytokines (6–8) and
contains low levels of adiponectin, an anti-inflam-
matory adipokine, in patients with CAD (9, 10).
Moreover, adiponectin expression in EAT decreases in
patients with hypertension (11); although its levels are
not modified in diabetes (12). These findings suggest
that EAT plays an important role in cardiovascular
disease and some of its risk factors. Thus, the behavior of
this fat pad seems to be different from SAT.
Recently, it was found that adipose tissue expresses
the receptor for advanced glycation end-products (AGER
or RAGE) (13). This is a multiligand receptor of the
immunoglobulin superfamily (14) that binds advanced
glycation end-products (AGE). AGE are modifications ofDOI: 10.1530/EJE-10-0904
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glycated and oxidized after contact with aldose sugars
(15). AGE form in vivo in hyperglycemic environments
and during aging, and they have been related with the
initial steps of atherosclerosis and with inflammatory
responses (16). Among the effects caused by these
products, we can emphasize generation of reactive
oxygen species (ROS), migration of cells, and expression
of adhesion and inflammatory molecules (17). The
AGE–RAGE engagement is widely related with cardio-
vascular disease and ROS generation, mainly mediated
by NADPH oxidase (18). This enzyme consists in two
membrane-bound subunits, the gp91-PHOX protein
(NOX2) or some of its homologs (named NOX from 1 to
5) and p22-PHOX protein (19). Once activated, NADPH
oxidase produces superoxide anions from oxygen and
NADPH or NADH. Enhanced ROS production is an
important factor associated with some cardiovascular
diseases (20) such as CAD. Furthermore, we have
previously observed that EAT presents higher oxidative
stress than SAT (21).
Taking all this together, we can hypothesize that EAT,
due to its physical location, its endocrinological activity,
and its possible reactivity to AGE, could play an
important role in CAD, a situation typically related
with enhancement of both ROS production and inflam-
matory reactions. The aim of this study was to analyze
the relationship between CAD and the expression of
RAGE, NADPH oxidase subunits, and catalase in EAT
and SAT of patients undergoing heart surgery.Subjects and methods
Patients
Thirty-seven patients undergoing heart surgery with
sternotomy were included in the study. Exclusion criteria
were previous heart surgery or concomitant infective
diseases. All participants gave their informed consent.
The study protocol was approved by the local ethical
committee and carried out according to the Declaration
of Helsinki. Clinical data were obtained upon admission
to hospital before surgery. Diagnosis of CAD was
based on previous coronary angiogram. Reductions in
luminal coronary artery diameters in excess of 50% were
considered significant. Heart valve disease was the cause
of surgery in all patients without CAD.Adipose tissue biopsies
EAT biopsy (0.1–1 g wet weight) was obtained from
upper region of the right ventricle, and SAT biopsy (2 g
wet weight) was obtained from the thorax. Samples
were immediately split, when possible, into two pieces.
One piece was frozen in liquid nitrogen before storage at
K80 8C until use, and the other one was formalin-fixed
and paraffin-embedded.www.eje-online.orgmRNA extraction and real-time RT-PCR
mRNA was isolated from 50 to 100 mg of EAT and
SAT with the oligotex mRNA Spin-column kit
(Qiagen GmbH). The final concentration was 1 mg
tissue/1 ml solution. Then, 4.14 ml of mRNA solution
was transcribed using 200 U of Moloney murine
leukemia virus reverse transcriptase (Invitrogen Corp.)
in 30 ml of a pH 8.4 solution containing 20 mM
Tris–HCl, 50 mM KCl, 2.5 mM MgCl2, dNTPs (1 mM
each), 20 U of RNase inhibitor, and random primers
under the following conditions: 50 min at 37 8C, 10 min
42 8C, and 5 min at 95 8C.
Comparative EAT and SAT gene expression levels with
respect to b-actin were analyzed by real-time PCR
(Chromo 4; MJ Research, Inc., Waltham, USA) in
duplicated using 4 ml of cDNA, SYBR Green (Roche
Diagnostics Corp., Inc.) as fluorochrome, and the primers
sequence and amplification conditions shown in Table 1,
during 40 cycles. Fluorescence curves were analyzed using
Opticon Monitor software (MJ Research). Melting curves
were tested in order to probe the correct amplicon. Gene
expression levels were calculated with respect to b-actin
expression and represented in arbitrary units (a.u.).Immunohistochemistry
Paraffin-embedded tissue sections 3 mm-thick were
deparaffined and rehydrated. Epitope retrieval was
done in basic solution for 20 min at 97 8C. Immunos-
taining was performed with anti-human RAGE
antibody (1:500; Abcam, Cambridge, UK) for 30 min
following the protocols. LSAB (Dako Diagnostics,
Glostrup, Denmark) using 3,3 0-diaminobenzidine tetra-
hydrochloride was used for detection. Negative controls
were carried out omitting the primary antibody. Results
from different samples were analyzed for quantification
of RAGE expression using the free ImageJ (1.37v)
software from NIH, USA.Protein extraction and western blot
Protein isolation from a series of SAT samples was
performed as previously described (12). In brief,
100–150 mg of EAT and SAT were rinsed in 5 ml of
phosphate saline solution containing 0.5 mM EDTA,
5 mM KCl, 10 mM HEPES acid, 2 mM MgCl2, 10 mM
NaHCO3, 0.5 mM KH2PO4, 0.5 mM NaH2PO4, 10 mM
glucose, 110 mM NaCl, and 0.16 mM CaCl2 at pH 7.4,
and then centrifuged at 300 g for 1 min to remove
residual blood. Tissues were resuspended (weight/
volume) in 600 ml lysis buffer (125 mM Tris pH 6.8,
10% glycerol, 2% SDS, 100 mM dithiothreitol, 1! anti-
protease cocktail from Sigma–Aldrich) and sheared
by homogenizer pestle using sample-grinding kit
(GE Healthcare, Waukesha, WI, USA).
Prior to protein separation, immunoglobulin
depletion from the samples was performed to allowDownloaded from Bioscientifica.com at 01/22/2021 11:53:29AM
via free access
Table 1 Gene database accession numbers, sequences for forward (F) and reverse (R) primers, PCR conditions, and amplified
fragment lengths used.
Genes Primers Accession numbers PCR conditions Length (bp)
AGER (RAGE) F-ggaatggaaaggagaccaag NM_001136 30 s 95 8C 199
R-cccttctcattaggcaccag 30 s 58 8C
30 s 72 8C
ACTB (b-actin) F-ttctgacccatgcccaccat NM_001101.3 30 s 95 8C 198
R-tggatgatgatatcgccgcgctc 30 s 58–60–62 8C
30 s 72 8C
CAT (Catalase) F-gcctgggacccaattatctt NM_001752 30 s 95 8C 203
R-gaatctccgcacttctcccag 60 s 58 8C
60 s 72 8C
CYBB (NOX2) F-tcacttcctccaccaaaacc NM_000397.3 30 s 95 8C 211
R-gggattgggcattcctttat 30 s 60 8C
30 s 72 8C
NOX4 F-cttccgttggtttgcagatt NM_016931 30 s 95 8C 245
R-tgggtccacaacagaaaaca 30 s 60 8C
30 s 72 8C
NOX5 F-ctacgtggtagtggggctgt NM_024505 30 s 95 8C 213
R-atgcaggaactggagcagat 30 s 62 8C
30 s 72 8C
CYBA (p22-PHOX) F-cgcttcacccagtggtactt NM_000101.2 30 s 95 8C 200
R-gagagcaggagatgcaggac 30 s 60 8C
30 s 72 8C
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Immunoglobulins were bound to protein A using
PureProteome Protein A Magnetic Beads (Millipore,
Billerica, MA, USA). From the protein solution, 20 ml
were diluted with 100 ml of phosphate-buffered solution,
and the mixture was incubated with protein A magnetic
beads for 30 min under agitation at room temperature.
Finally, magnetic beads binding immunoglobulins were
separated, and the depleted sample was recovered.
Proteins were concentrated 10! with centrifugal filter
devices (Amicon Ultra-0.5, Millipore).
Protein separation (40 mg) was carried out in 12%
SDS–PAGE gel and transferred to a polyvinylidene fluoride
membrane for 45 min at 280 mA. The membranes were
blocked for 2 h at room temperature with 5% milk in
Tris-buffered saline–Tween-20 containing 20 mM Tris–
HCl (pH 7.6), 150 mM NaCl, and 0.1% Tween-20. The
membranes were then exposed with rabbit RAGE antibody
(1:1000 dilution; Abcam) and mouse b-actin antibody
(1:1000; Santa Cruz Biotechnology, Delaware, CA, USA)
overnight, and then to peroxidase-conjugated goat anti-
rabbit and anti-mouse IgG (1:1500). Immunoreactive
proteins were visualized using an ECL detection system
(Amersham Pharmacia Ltd) and quantified by densitome-
try Image J software. RAGE protein levels were evaluated
in duplicate and quantified with respect to b-actin.Data analysis
Assumptions of normality of continuous variables were
checked with Kolmogorov–Smirnov tests. Continuous
variables were expressed as meanGS.D. Differences
between continuous variables were evaluated using
Student’s t-test. Categorical variables were expressedas percentages and compared using the c2-test.
Correlations between variables were calculated by
Pearson’s or Spearman’s tests according to the normal-
ity of the variable, and two-tailed P values are shown.
Statistical significance was defined as P!0.05. All
analyses were performed with the Statistical Package
for Social Sciences (SPSS) version 15.0 for Windows
(SPSS, Chicago, IL, USA).Results
Clinical characteristics and main differences
between patients with and without CAD
Thirty-seven patients undergoing heart surgery were
included in the study and analyzed. Mean age was
71.5G9.1 years; 62.2% were male, and mean body
mass index was 28.3G7.2 kg/m2. All clinical charac-
teristics are summarized in Table 2. Patients were
classified as belonging to one of two groups: patients
with CAD and patients without CAD. Differences in
main clinical characteristics were not observed between
groups, as shown in Table 2.
In this population, mRNA levels for AGER (RAGE),
NOX (2, 4, and 5), p22-PHOX (CYBA), and catalase (CAT)
were measured in EAT and SAT. Mean values of these
parameters and the comparison between CAD and non-
CAD groups of patients are shown in Table 3. From this
comparison, only RAGE in SAT was expressed in a
different manner between the two groups, being its levels
significantly lower in CAD patients (PZ0.002; Fig. 1).
To confirm these results, sections from paraffin-
embedded adipose tissue from SAT or EAT were
immunostained with anti-human RAGE. Quantificationwww.eje-online.org
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Table 2 Clinical characteristics of all patients, and comparison between patients with and without CAD. Values are
expressed as a percentage or as meanGS.D.
Variables All patients (nZ37) Non-CAD (nZ20) CAD (nZ17) P value
Age (years) 71.5G9.1 71.1G10.1 72.0G8.1 0.779
Gender (male) 62.2 50.0 76.5 0.094
BMI (kg/m2) 28.3G7.2 28.3G5.3 28.3G9.1 0.992
Hypertension 76.9 76.2 77.8 0.605
Diabetes mellitus type 2 24.3 19.0 33.3 0.257
Hyperlipidemia 64.9 52.6 77.8 0.104
Atrial fibrillation 21.2 20.0 23.1 0.581
Glucose (mg/dl) 112.5G32.3 109.4G19.0 116.2G43.3 0.517
Creatinine (mg/dl) 1.3G0.4 1.2G0.3 1.4G0.6 0.437
HbA1c (%) 5.4G0.6 5.4G0.4 5.4G0.9 0.946
Total cholesterol (mg/dl) 168.2G41.4 179.9G40.3 155.8G39.9 0.076
LDL (mg/dl) 100.2G33.5 114.4G32.2 86.0G29.7 0.055
HDL (mg/dl) 37.7G12.0 39.4G15.7 36.1G7.3 0.558
Triglycerides (mg/dl) 117.8G55.1 109.6G50.0 126.4G60.3 0.366
P value for the comparison was obtained by c2 test or by Student’s t-test for categorical or continuous variables respectively. BMI, body
mass index; HDL, high-density lipoprotein; LDL, low-density lipoprotein.
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ical preparations confirmed that in SAT from patients
with CAD, RAGE expression was significantly reduced in
comparison with expression in EAT of the same patient
and with respect to SAT and EAT from patients without
CAD (Fig. 2).
RAGE expression in SAT was also analyzed at protein
level by western blot in a subset of patients (four CAD
and three non-CAD). In these measurements, relative
RAGE protein quantity, normalized with respect to
b-actin, showed that in SAT, RAGE was lower in CAD
patients than in patients without CAD (Fig. 3). These
results agreed with the observation done at mRNA level,
where RAGE expression in SAT was also lower in CAD
patients with respect to non-CAD patients.
We also analyzed the difference in the gene expression
between EAT and SAT. In this comparison, results
showed that RAGE and p22-PHOX were highly expressedTable 3 Relative expression values in EAT and SAT for the genes
indicated. Mean values for all patients and comparison between




patients Non-CAD CAD P value
Catalase EAT 8.60G0.69 8.63G0.61 8.57G0.82 0.875
Catalase SAT 9.21G0.62 9.46G0.65 8.96G0.52 0.141
NOX2 EAT 6.29G0.34 6.24G0.18 6.33G0.45 0.634
NOX2 SAT 6.13G0.41 6.29G0.41 6.00G0.39 0.209
NOX4 EAT 5.94G0.40 5.95G0.51 5.94G0.31 0.969
NOX4 SAT 6.31G0.25 6.33G0.28 6.30G0.24 0.820
P22-PHOX EAT 8.07G0.45 8.28G0.51 7.86G0.28 0.081
P22-PHOX SAT 7.65G0.40 7.80G0.48 7.50G0.27 0.175
NOX5 EAT 4.44G0.31 4.46G0.26 4.41G0.37 0.741
NOX5 SAT 4.50G0.32 4.48G0.22 4.52G0.40 0.833
RAGE EAT 7.34G0.53 7.37G0.51 7.24G0.55 0.497
RAGE SAT 7.02G0.46 7.36G0.73 6.74G0.32 0.002
P value for the comparison was obtained by Student’s t-test.
www.eje-online.orgin EAT than in SAT, and NOX4 and catalase were highly
expressed in SAT with respect to EAT (Table 4).
With regard to the possible influence of the
co-morbidities of patients, the expression of the genes
under study was analyzed for the possible influence of
hypertension, hyperlipidemia, type 2 diabetes mellitus,
and atrial fibrillation. We only found an interesting
modification depending on diabetes mellitus: RAGE
mRNA levels in both EAT and SAT were lower in
patients with type 2 diabetes in comparison with
non-diabetic patients (Table 5). These results suggest a
down-regulating effect of diabetes on the RAGE
expression of the adipose tissue. From the other genes
analyzed, NOX2 mRNA levels in SAT were lower in
non-diabetic patients with respect to diabetics and, on
the contrary, NOX5 in SAT was lower in diabetic
patients (Table 5).Relationship between variables
We analyzed the relationship between mRNA
expression of NADPH oxidase subunits, catalase, and
RAGE regarding to the adipose tissue source. In this
sense, we observed that p22-PHOX levels in EAT
positively correlated with levels in SAT in all
patients (rZ0.766; PZ0.001). Although this corre-
lation was maintained in the non-CAD group of patients
(rZ0.809; PZ0.028), it disappeared in the CAD group
(rZ0.430; PZ0.336; data not shown). If we accept
that p22-PHOX could be an indicator of total NADPH
oxidase expression in the tissue, total levels of NADPH
oxidase would be directly related in EAT and SAT in the
absence of CAD, but not in CAD patients.
Something similar happened with RAGE: its mRNA
levels in EAT and in SAT were positively related
(rZ0.425; PZ0.014; Fig. 4A) considering all patients.
However, whereas in the non-CAD patients, this
association became stronger (rZ0.652; PZ0.002;














































Figure 1 Box plots for RAGE mRNA expression levels in EAT (A)
and in SAT (B) in the groups of patients with CAD or without CAD.






































Figure 2 Representative sections of paraffin-embedded epicardial
(A and C) or subcutaneous (B and D) adipose tissue from patients
RAGE in subcutaneous and epicardial adipose tissue 533EUROPEAN JOURNAL OF ENDOCRINOLOGY (2011) 164(rZ0.079; PZ0.788; Fig. 4C). These results agree with
a change in RAGE expression in SAT under CAD.
Total cholesterol, low-density lipoprotein, and triglycer-
ide levels were inversely related to NOX2 (rZK0.619;
PZ0.032), NOX4 (rZK0.742; PZ0.035), and p22-
PHOX (rZK0.587; PZ0.045) mRNA levels in EAT
respectively; whereas mRNA levels of NOX4 in SAT
correlated positively with serum levels of triglycerides
(rZ0.578; PZ0.049) and total cholesterol (rZ0.633;
PZ0.027). These data seem to indicate a different oxi-
dative response of SAT and EAT to lipid circulating levels.
In our study, there was no significant relationship
between glucose or HbA1c levels and the gene expressions
analyzed. Only a significant inverse relationship was
observed between HbA1c percentage and RAGE mRNA
levels in EAT, but not in SAT (rZK0.515; PZ0.041).with CAD (C and D) or without CAD (A and B) were immunostained
with anti-RAGE. Positive immunostaining for RAGE was less
pronounced in SAT from patients with CAD (D) than in patients
without CAD (B) in adipocytes and in vessels (insets). RAGE
expression in EAT was maintained to the same levels in non-CAD
patients (A) and in CAD patients (C). Columns represent mean
values (S.D. in vertical bars) of the percentage of RAGE-stained
area in each type of preparation. *P!0.05 with respect to EAT. Full
colour version of this figure available via http://dx.doi.org/10.1530/
EJE-10-0904.Discussion
For the first time, we have found that EAT from patients
with cardiovascular disease who underwent heart
surgery, expresses RAGE mRNA and protein. Moreover,
this expression in EAT and in SAT was related to CAD.Thus, RAGE expression levels were lower in SAT of
patients with CAD in comparison with non-CAD
patients. However, we have not found significant
changes in EAT. On the contrary, NADPH oxidase
subunits and catalase gene expression in EAT and SAT
were not influenced by CAD, only the expression pattern
of p22-PHOX in these tissues could be affected by CAD.
Diabetes can also reduce, independent of CAD, RAGE
expression in human adipose tissue.
Patients undergoing heart surgery were selected to
participate in the study and divided into two groups
with similar clinical characteristics and co-morbidities
unless the presence of CAD. In these conditions, mRNA
levels of RAGE, some NADPH oxidase subunits
expressed in adipose tissue, and catalase were measured
in SAT and EAT. Unless for RAGE, no statistical
differences in mRNA levels of these genes were observed
after comparing tissues between the groups of CAD and
non-CAD patients. RAGE mRNA levels in SAT werewww.eje-online.org























Figure 3 RAGE protein levels in SAT from CAD and non-CAD
patients analyzed by western blot. (A) Representative blots using
antibodies against RAGE and b-actin of SAT from four patients,
two without CAD and two with CAD. (B) Relative optical densities
of RAGE with respect to b-actin signal from seven patients (four
CAD and three non-CAD). a.u., arbitrary units relative to b-actin.
r = 0.425 
P = 0.014
r = 0.652






























































RAGE mRNA in SAT
8
Figure 4 Relationship between RAGE mRNA levels in SAT and in
EAT considering all patients (A), considering the non-CAD group of
patients (B), and considering the CAD group of patients (C). Straight
lines represent total adjustment with the confidence interval
represented as curved lines. rZPearson’s correlation coefficient.
Value of P is indicated in each case. P!0.05 was considered
statistically significant.
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without CAD; whereas no differences were observed
between levels in EAT of the same groups. In fact, the
positive association between RAGE mRNA levels in EAT
and in SAT from patients without CAD disappeared in
CAD patients. These results suggested that CAD induces
down-regulation of RAGE expression in SAT, but not in
EAT. This hypothesis was analyzed at protein level by
immunohistochemistry and western blot, and lower
presence of RAGE was evidenced in SAT of patients with
CAD, while RAGE expression was maintained in EAT of
these patients and in patients without CAD.
The physiological meaning of this finding cannot be
inferred from our study. However, RAGE expression in
tissues allows the engagement of its multiple ligands
(AGE, S100/calgranulins, and others), and this binding
can mediate pro-inflammatory responses (22), activate
ROS production (18) and damage the cardiovascular
system (23). Also, several variants of the RAGE gene
have been implicated in the development of diabetes-
associated atherothrombotic disorders. From these
variants, the functional polymorphism Gly82Ser (data-
base for SNP rs2070600) highlights. A significant
association between the haplotype carrying the G82S
polymorphism and an increased incidence of CAD and
elevated serum CRP levels in the Chinese Han
population has been described by Gao et al. (24).
However, previous genetic epidemiological studies
showed negative results from studies involving Cauca-
sian subjects with cardiovascular disease (25). Further
more, 82S allele seems to have a protective role inwww.eje-online.orgKorean CAD patients (26). Therefore, the pathophysio-
logical role of these variants in CAD remains elusive,
and further investigations must be performed.
It has been suggested that the diverse splicing variants
of RAGE are possible in many tissues, and their products
may influence the RAGE-mediated pathogenesis (27).
Besides the RAGE expression variants, the tissue
where they are expressed could have differentDownloaded from Bioscientifica.com at 01/22/2021 11:53:29AM
via free access
Table 4 Comparison between the gene expression levels in EAT
and SAT of the genes indicated. Values are expressed as mean
GS.D. in a.u.
Variables EAT SAT P value
NOX2 6.29G0.34 6.13G0.41 0.213
NOX4 5.94G0.40 6.31G0.25 0.005
NOX5 4.43G0.32 4.50G0.32 0.344
P22-PHOX 8.07G0.45 7.65G0.40 0.000
Catalase 8.60G0.69 9.21G0.62 0.018
RAGE 7.34G0.53 7.02G0.46 0.002
P value for the comparison was obtained by Student’s t-test. Statistically
significant (P!0.05) values are in boldface.
Table 5 Relative expression values in patients with and without
type 2 diabetes mellitus for the genes indicated. Mean values for the
comparison between patients with and without diabetes mellitus.






Catalase EAT 8.76G0.71 8.20G0.52 0.182
Catalase SAT 9.34G0.68 8.89G0.26 0.237
NOX2 EAT 6.19G0.34 6.51G0.25 0.133
NOX2 SAT 5.96G0.35 6.53G0.21 0.013
NOX4 EAT 5.99G0.46 5.83G0.18 0.526
NOX4 SAT 6.33G0.27 6.28G0.22 0.760
NOX5 EAT 4.53G0.27 4.19G0.28 0.062
NOX5 SAT 4.63G0.18 4.04G0.25 0.001
P22-PHOX EAT 7.97G0.44 8.30G0.44 0.228
P22-PHOX SAT 7.60G0.31 7.77G0.63 0.512
RAGE EAT 7.44G0.53 6.93G0.26 0.001
RAGE SAT 7.15G0.41 6.61G0.37 0.002
P value for the comparison was obtained by Student’s t-test. Statistically
significant (P!0.05) values are in boldface.
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is the reason because it is worth to test the expression of
RAGE in adipose tissue and to analyze the differences
between tissues from different locations.
In this observational work, we could not study the
causes of the RAGE expression modification in SAT of
patients with CAD. However, according to our results
and previously reported data, we can suggest at least
one factor that could be related with RAGE-altered
expression. That is, down-regulation of RAGE in SAT
could be related to changes in the ROS production of the
tissue. One of the ways for studying the oxidative stress
consists of measuring the enzymes involved in ROS
generation, as NADPH oxidase. P22-PHOX is the
unique subunit present in most of the NADPH oxidase
complexes (28); so, it can be used as a marker of almost
total NADPH oxidase content. The fact is that the
mRNA levels of p22-PHOX in EAT were directly
correlated to the levels in SAT when considering the
total population of the study, but this correlation failed
when considering only the group of patients with CAD.
This result suggests that NADPH oxidase expression
change in SAT or EAT could be due in part to CAD. Thus,
ROS production changes could also be related to the
down-regulation of RAGE in SAT, evidencing a triangle
of interaction between RAGE, oxidative stress, and
altered gene expression that has been previously
proposed by other authors (29). In this context,
oxidative stress has been reported to be higher in EAT
than in SAT (21), and this could help to maintain RAGE
expression levels in EAT under CAD.
Although in our study, NADPH oxidase subunits and
catalase mRNA levels were not statistically related to
RAGE expression, we could not discard the possibility
that ROS production can be related to RAGE expression.
Independent of CAD, the results revealed a higher
expression of RAGE and p22-PHOX in EAT compared
with SAT, while there was lower catalase expressed in
EAT with respect to SAT. This could indicate a higher
oxidative stress in EAT than in SAT, possibly mediated
by RAGE (23) and NADPH oxidase (where p22-PHOX
participate in almost all the isoforms). Further more,
lower catalase expression in EAT, an antioxidantenzyme, also contributes to an oxidative state. This
finding agrees with previous observations (21).
Intriguing relationships between circulating lipid
levels and Nox isoforms expression in adipose tissue
were observed. Whereas Nox isoform expressions in EAT
were inversely related to lipid levels, the opposite
occurred in SAT. It could be supposed that SAT exposed
to lipids can be more sensitive to ROS production.
However, the higher mRNA levels of p22-PHOX and the
lower levels of catalase in EAT with respect to SAT
indicated that ROS production in EAT could be higher
than in SAT in patients with cardiovascular diseases, as
previously shown (21). It is also known that visceral
adipose tissue is an important contributor to oxidative
stress (30). The opposite reaction of EAT and SAT to
circulating lipid levels could help to explain the different
response in RAGE expression observed in this work.
Although it was not the aim of this study, our results
also suggested that diabetes mellitus can influence the
levels of RAGE expression in the adipose tissue, since the
expression of this receptor was lower in both EAT and
SAT from diabetic patients with respect to non-diabetic
patients. However, this finding seems to be independent
of the association observed between RAGE expression in
SAT and CAD, because the distribution of diabetic
patients in the groups of CAD and non-CAD patients of
our sample turned out to be exactly the same. This
result is very interesting since AGE–RAGE axis can play
a pivotal role in the setting of diabetes-derived vascular
complications (31). We do not have a physiological
explanation for RAGE-reduced expression in diabetic
adipose tissue. Moreover, it is unknown which could be
the real meaning of RAGE down-regulation in the
setting of diabetes, since to block the AGE–RAGE axis
has disparate effects in diabetic complications, with
different clinical implications (32).
With regard to the limitations of this work, firstly,
difficulty to include heart surgery patients made thewww.eje-online.org
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Further research with a larger population could
confirm our results. Second, the study was performed
in patients undergoing heart surgery, so extrapolation
of the results to other type of patients would need to be
supported by appropriate data collection. Third, other
than for RAGE, we have studied the mRNA levels, but
not the protein content. The size of the adipose tissue
sample obtained from heart surgery is always small, and
it was impossible to combine mRNA and protein
analysis for all genes.
In conclusion, this study demonstrated for the first
time that RAGE expression in SAT, but not in EAT, is
down-regulated in patients with CAD in comparison
with non-CAD patients. Moreover, RAGE expression in
diabetic patients was found to be lower than in non-
diabetic patients both in EAT and in SAT. No changes
were observed for NADPH oxidase subunits or catalase
expression between CAD and non-CAD patients.
However, a possible relationship between ROS pro-
duction and RAGE expression in adipose tissues cannot
be ruled out. Further mechanistic investigations would
be necessary to explain these new relationships found
between RAGE expression in adipose tissue and CAD
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